期刊
BREAST CANCER MANAGEMENT
卷 7, 期 1, 页码 -出版社
FUTURE MEDICINE LTD
DOI: 10.2217/bmt-2017-0014
关键词
atezolizumab; avelumab; biomarker; breast cancer; checkpoint inhibitor; CTLA-4; durvalumab; immunotherapy; ipilimumab; nivolumab; PD-1; PD-L1; pembrolizumab
类别
资金
- Bristol-Meyers-Squibb
- Dutch Cancer Society (KWF)
Immunotherapy using anti-PD(L) 1 has revolutionized treatment for various tumor types. Early data have shown durable responses in a small subgroup of breast cancer patients. So far, the response rates appear higher for breast tumors that are triple negative, PDL1-positive and/or harbor high levels of immune cells. Both comprehensive analyses of the breast tumor microenvironment and exploiting research on biomarkers in other cancer types, such as melanoma and lung cancer, may contribute to the discovery of accurate biomarkers to select breast cancer patients for immunotherapy. Here we summarize key features of the breast tumor microenvironment as well as putative predictive biomarkers established in other tumor types. Insights from both fields can guide future studies to enable personalized breast cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据